We are seeking to appoint a Higher Scientific Officer within the Centre for Protein Degradation to deliver biology aspects of the Centre's projects. The postholder will be working in a multidisciplinary team on discovery and validation of novel molecular glue and PROTAC targets and E3 ligases for challenging oncology indications, contributing to our exploratory and drug discovery efforts.
Key Requirements
This position is suitable for a strong team player who is technically-minded and passionate about innovative solutions for cancer drug discovery. They should have a PhD in biology or biochemistry with solid background in cancer cell biology and hands-on experience with in vitro genetic manipulation techniques applicable for target validation and interrogation of cell signalling pathways. Experience in targeted protein degradation, biochemical and pharmacology assays would be an additional advantage.
Department Information
This position will be based in the ICR's Centre for Protein Degradation - a part of the ICR Centre for Cancer Drug Discovery (CCDD) specialising in developing novel drug modalities that re-wire tumour cells' signaling by targeted degradation of key oncogenic drivers. Our experienced biologists work closely with medicinal chemists, biophysicists, computational scientists and oncology specialists on expanding the repertoire of novel degradable drug targets and E3 ligases (enzymes that mediate protein degradation), identifying drugs using innovative screening platforms and characterising their mechanisms of action. Our research provides a nucleus for other teams internally and externally to explore the therapeutic potential of targeted protein degradation medicines. Together with the ICR academics, ICR CCDD and collaborations with pharmaceutical industry we develop these rapidly from the laboratory hypothesis-testing to early clinical trials, for the benefit of cancer patients.
We encourage all applicants to look at the attached job pack for more detailed information about this role. For an informal discussion about the role please feel free to contact Dr Agnieszka Konopacka, Group Leader, Induced Proximity Therapeutics, via email: [email protected].